Know more

Having just finished her medical internship in gastroenterology, Clémence Breton is currently doing a Master 2 internship. She is working on the role of the intestinal microbiota in the metabolism of exogenous glucocorticoids in Crohn's disease.

Indeed, the evidence of the essential role of the microbiota in many diseases and in particular in inflammatory bowel diseases is increasingly important. Budesonide (Entocort® or Mikicort®) is recommended as first-line treatment for moderately active ileocecal Crohn's disease. The team has previously shown a difference in effect between Budesonide tablets (Entocort®) and the molecule depending on the composition of the microbiota. The objective of this master's project is to evaluate the association between microbiota of patients with Crohn's disease and response to glucocorticoids and to develop and test microbial biomarkers potentially predictive of the response to glucocorticoids. If successful, this project could help select patients for treatment with budesonide and open new perspectives for manipulation of the intestinal microbiota (faecal transplantation or microbial supplementation) in order to increase the efficacy of treatment with budesonide.